Experiment 1231881
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV INFUSION |
| Organism | Empty organism |
| Citation | SALTZ,L: SIROTT,M: YOUNG,C: TONG,W: NIEDZWIECKI,D: YAO,TJ: TOA,Y: TROCHANOWSKI,B: WRIGHT,P: BARBOSA,K: TOOMASI,F: KELSEN,D:. (1993). PHASE I CLINICAL AND PHARMACOLOGY STUDY OF TOPOTECAN GIVEN DAILY FOR 5 CONSECUTIVE DAYS TO PATIENTS WITH ADVANCED SOLID TUMORS, WITH ATTEMPT AT DOSE INTENSIFICATION USING RECOMBINANT GRANULOCYTE COLONY-STIMULATING FACTOR.. 85(18) |
| Amount utilized | |
| Compound isolated | |
| Disease | THE DOSES OF TOPOTECAN RECOMMENDED FOR USE IN PHASE II CLINICAL TRIALS IN SOLID TUMORS ARE 1.5 AND 1.25 MG/M2 DAILY IN PREVIOUSLY UNTREATED AND PREVIOUSLY TREATED PATIENTS, RESPECTIVELY. DOSE INTENSIFICATION WAS NOT POSSIBLE WITH RG-CFS. |
| Dose amount | VAR |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Dose expression | DOSE |